Showing 1581-1590 of 2150 results for "".
- Zeiss Introduces New Devices and Software Applications as Part of Medical Ecosystemhttps://modernod.com/news/zeiss-introduces-a-series-of-innovations-and-software-applications-as-part-of-the-medical-ecosystem/2480290/As part of its innovation week, Zeiss introduced integrated solutions designed to bring value to the Zeiss Medical Ecosystem, connecting devices, data, and applications. Zeiss introduced a new integrated cataract workflow solution for lens replacement with the launch of t
- Oxurion Announces Publication of Positive Phase 1 Clinical Data Evaluating THR-687 for Treatment of DMEhttps://modernod.com/news/oxurion-announces-publication-of-positive-phase-1-clinical-data-evaluating-thr-687-for-treatment-of-dme/2479451/Oxurion announced that the positive phase 1 study of THR-687, a novel, highly potent integrin agonist for the treatment of DME has just been published in Ophthalmology Science. The multicenter, dose escalation study was designed to evaluate the safety and preliminary efficacy of t
- Alcon to Launch TOTAL30 as the First Monthly Replacement, Water Gradient Contact Lenshttps://modernod.com/news/alcon-to-launch-total30-as-the-first-monthly-replacement-water-gradient-contact-lens/2479449/Alcon announced plans to launch TOTAL30, the first-and-only monthly replacement, water gradient lens. Using Alcon’s proprietary water gradient material first introduced with DAILIES TOTAL1 contact lenses, TOTAL30 delivers a premium wearing experience for reusable contact lens wearers, according t
- Johnson & Johnson Vision Launches Veritas Vision Systemhttps://modernod.com/news/johnson-johnson-vision-introduces-veritas-vision-system-with-features-to-address-key-unmet-needs-in-cataract-surgery/2479401/Johnson & Johnson Vision announced the global availability of the Veritas Vision System, a next-generation phacoemulsification system designed to address three critical areas: patient safety, surgeon efficiency and comfort. The company will offer live demos of the new system in a wet lab at t
- Envision Sets Agenda for 2021 Virtual Conference Easthttps://modernod.com/news/envision-sets-agenda-for-2021-virtual-conference-east/2479371/Envision announced that it has finalized the agenda for its August 2021 Conference, a 2-day event to be livestreamed on August 20-21. Envision Virtual Conference East 2021 is a multidisciplinary event focused on disseminating the latest advancements in rehabilitation techniques and research and t
- Recycling of the Eye’s Light Sensors Is Faulty in Progressive Blindness of Older Adults, University of Maryland School of Medicine Researchers Showhttps://modernod.com/news/recycling-of-the-eyes-light-sensors-is-faulty-in-progressive-blindness-of-older-adults-university-of-maryland-school-of-medicine-researchers-show/2479329/With the National Eye Institute reporting that about 11 million older adults in the U.S. endure a condition that leads to progressive blindness, known as age-related macular degeneration, University of Maryland School of Medicine (UMSOM) researchers are starting to understand what goes wrong in t
- Bausch + Lomb and Lochan Enter Into Agreement to Develop the Next-Generation of Eyetelligence Clinical Decision Support Softwarehttps://modernod.com/news/bausch-lomb-and-lochan-enter-into-agreement-to-develop-the-next-generation-of-eyetelligence-clinical-decision-support-software/2479271/Bausch + Lomb announced that its affiliate has entered into an agreement with Lochan LLC to develop the next-generation of Bausch + Lomb’s eyeTELLIGENCE clinical decision support software. Using the existing cloud-based infrastructure of eyeTELLIGENCE, this analytical software is being designed t
- Eyenovia Announces Topline Results From VISION-1 Phase 3 Study of MicroLine for the Treatment of Presbyopiahttps://modernod.com/news/eyenovia-announces-positive-topline-results-from-vision-1-phase-3-clinical-study-of-microline-for-the-treatment-of-presbyopia/2479241/Eyenovia announced that its VISION-1 study evaluating the company’s proprietary pilocarpine formulation, MicroLine, for the temporary improvement of near vision in adults with presbyopia, achieved its primary endpoint. Preparations are underway for a second phase 3 registration study, VISION-2. T
- Melling Medical to Distribute Optos Technology to Federal Health Facilitieshttps://modernod.com/news/melling-medical-to-distribute-optos-technology-to-federal-health-facilities/2479175/MellingMedical today announced a new distribution agreement with Optos Inc. to deliver their state-of-the-art equipment to facilities across the federal health care system. “As they work to accommodate growing caseloads, doctors in the federal health system are looking for t
- Hoya Vision Care Releases Results of 3-Year MiYOSMART Spectacle Lens Follow-up Studyhttps://modernod.com/news/hoya-vision-care-releases-results-of-3-year-miyosmart-spectacle-lens-follow-up-study/2479124/Hoya Vision Care shared the results of a 3-year follow-up clinical study on its MiYOSMART spectacle lens with patented Defocus Incorporated Multiple Segments (D.I.M.S.) Technology after releasing the information at the recent European Academy of Optometry and Optics (EAOO) ’21 conference. T